Detalhe da pesquisa
1.
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.
Cell
; 182(2): 297-316.e27, 2020 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32619424
2.
OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity.
Nat Immunol
; 22(10): 1327-1340, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34556886
3.
PUF-8, a C. elegans ortholog of the RNA-binding proteins PUM1 and PUM2, is required for robustness of the cell death fate.
Development
; 150(19)2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37747106
4.
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 386(4): 351-363, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904799
5.
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Blood
; 141(16): 1971-1981, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626583
6.
Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region.
Immunity
; 45(3): 497-512, 2016 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27637145
7.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood
; 140(8): 839-850, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35605176
8.
Establishment and verification of a method for analyzing nasal blackheads images.
Skin Res Technol
; 30(3): e13648, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38481087
9.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538797
10.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Am J Hematol
; 98(3): 449-463, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594167
11.
COVID-19 vaccine uptake and hesitancy in Chinese patients with asthma.
J Asthma
; 60(12): 2111-2120, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272671
12.
Comparative study of instrumental measurement and sensory evaluation methods for the repairing effect of mildly damaged hair bundles.
Skin Res Technol
; 29(7): e13394, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37522499
13.
Evaluation of the antiwear-ability/scratch-resistance efficacy of makeup products by in vitro test method application.
Skin Res Technol
; 29(8): e13420, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37632176
14.
Establishment and validation of visual assessment for the severity of lacrimal groove wrinkles in Chinese females.
Skin Res Technol
; 29(1): e13244, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36448212
15.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206772
16.
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.
BMC Cancer
; 22(1): 231, 2022 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35236331
17.
Structural and functional age-related changes in some facial signs of Chinese men: A pilot study.
Int J Cosmet Sci
; 44(5): 530-541, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35841376
18.
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Blood
; 133(26): 2765-2775, 2019 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30862645
19.
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).
Haematologica
; 106(11): 2834-2844, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33121235
20.
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
Am J Hematol
; 96(4): 418-427, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368455